Home › Free Stock Grades › OCUL
Ocular Therapeutix, Inc. (OCUL) Stock Grade
OCUL · Healthcare
C+
Market Cap
$2.3B
P/E Ratio
—
Revenue Growth (YoY)
-18.7%
Net Margin
-513.2%
Return on Equity
—
Dividend Yield
None
About Ocular Therapeutix, Inc.'s fundamentals
Ocular Therapeutix is a biotechnology company with a market capitalization of $2.3 billion that reported an 18.7% decline in revenue year-over-year. The company posted a net loss in its latest annual statement with a net margin of -513.2%, indicating significant operating losses relative to its revenue base. As a pre-profitability biotech firm, the company does not pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable.